Open AccessMonoclonal Anti‐P‐glycoprotein Antibody‐dependent Killing of Multidrug‐resistant Tumor Cells by Human Mononuclear Cells
Author(s) -
Heike Yuji,
Hamada Hirofumi,
Inamura Noriaki,
Sone Saburo,
Ogura Takeshi,
Tsuruo Takashi
Publication year - 1990
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1990.tb02528.x
Subject(s) - monoclonal antibody , peripheral blood mononuclear cell , p glycoprotein , multiple drug resistance , glycoprotein , antibody , tumor cells , immunology , cancer research , biology , virology , microbiology and biotechnology , in vitro , drug resistance , biochemistry
Mouse monoclonal antibodies (MRK16 and MRK17) against human multidrug‐resistant cancer cell lines were tested for antibody‐dependent cytotoxicity mediated by human blood mononuclear cells, using a 4‐h 51 Cr release assay. MRK16 (IgG 28 isotype) was shown to be more effective than MRK17 (IgG 1 isotype). Moreover, when four pairs of drug‐resistant and their parent sensitive human cancer cells were tested for antibody‐dependent cell‐mediated cytolysis (ADCC) using MRK16, only the drug‐resistant cell lines were susceptible to ADCC reaction. When highly purified lymphocytes (>99%) and monocytes (>97%) were isolated from blood mononuclear cells by centrifugal elutriation and adherence, MRK16 promoted both lymphocyte‐ and monocyte‐mediated tumor cell killing, whereas MRK17 induced only a lymphocyte‐mediated ADCC reaction. These results suggest that MRK16 of IgG 28 subtype may be a useful therapeutic agent in eradication of drug‐resistant cancer cells expressing P‐glycoprotein through ADCC reaction.